AI assistant
SOLARA ACTIVE PHARMA SCIENCES LIMITED — Regulatory Filings 2018
Dec 14, 2018
61842_rns_2018-12-14_fd471a31-4648-4a91-a704-3685cf316d98.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [104 x 21] intentionally omitted <==
==> picture [106 x 9] intentionally omitted <==
==> picture [187 x 78] intentionally omitted <==
==> picture [471 x 698] intentionally omitted <==
PRESS FOR IMMEDIATE
WWW.SOLARA.CO.IN | BSE:541540 NSE:SOLARA BLOOMBERG:SOLARA:IN | SECTOR:PHARMACEUTICALS
==> picture [165 x 55] intentionally omitted <==
CIRCULATION
Solara Research Centre completes USFDA Ins ection with zero 483s p
Chennai, India – December 14, 2018: Solara Active Pharma Science Limited (Solara), a leading Active Pharmaceutical Ingredient provider today announced the successful completion of US FDA inspection at Solara Research Centre(SRC), Chennai with zero 483s inspectional observations.
Established in 2005, SRC is a state-of-the-art R&D centre with capabilities to develop niche products characterised by complex chemistry across the diverse therapeutic categories. The centre is equipped with high-end infrastructure with advanced analytical capabilities, strong IP assessment skills and global regulatory expertise. It is led by experienced technical leadership which has demonstrated significant strategic value for the customers and the partners. SRC is also an important pivot in Solara’s Contract Research and manufacturing services(CRAMS) vertical.
SRC was earlier inspected by USFDA as “Control Testing Laboratory” in December 2012 and August 2016.
About Solara
Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five API facilities in India with approvals including the USFDA, EU GMP, KFDA and PMDA in Japan.
Investor / Analyst contact Statutory contact Dikshita Jain Murali Krishna S Christensen Investor Relations Raghavan. V [email protected] [email protected] +91 22 4215 0210 +91 44 4344 6700
Disclaimer: Certain statements in this document that are not historical facts are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.